"Le Centre Hospitalier d'Arras est un établissement public de santé proposant une offre de soins de qualité et de proximité en médecine, chirurgie, obstétrique, psychiatrie et gériatrie."

During the past decade, CH ARRAS conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 2 clinical trials were completed, i.e. on average, 4.7% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 1 clinical trials were completed. i.e. 5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH ARRAS" #1 sponsor was "University Hospital, Lille" with 16 trials, followed by "Centre Hospitalier Arras" with 6 trials sponsored, "The Lymphoma Academic Research Organisation" with 4 trials sponsored, "Lille Catholic University" with 3 trials sponsored and "University Hospital, Brest" with 3 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH ARRAS" #1 collaborator was "Ministry of Health, France" with 6 trials as a collaborator, "Région Nord-Pas de Calais, France" with 2 trials as a collaborator, "ARAIRLOR" with 1 trials as a collaborator, "Abbott" with 1 trials as a collaborator and "Air Liquide SA" with 1 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 34 trials.

According to Clinical.Site data, the most researched conditions in "CH ARRAS" are "Alzheimer Disease" (2 trials), "Cancer" (2 trials), "Multiple Myeloma" (2 trials), "Obesity" (2 trials) and "Venous Thromboembolism" (2 trials). Many other conditions were trialed in "CH ARRAS" in a lesser frequency.

Most popular intervention types in "CH ARRAS" are "Drug" (18 trials), "Other" (15 trials), "Procedure" (5 trials), "Device" (4 trials) and "Behavioral" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Lenalidomide" (2 trials), "Rituximab" (2 trials), "ABTEST card" (1 trials) and "Air" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH ARRAS" are 55 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "CH ARRAS". 2 are not yet recruiting, 15 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in CH ARRAS, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in CH ARRAS, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 17 trials that are defined as “Not Applicable".